ALEMBIC PHARMACEUTICALS

BSE: 533573 30 Sep 2025

Healthcare

₹ 972.5

ALEMBIC PHARMACEUTICALS LIMITED specializes in Pharmaceuticals within the Healthcare sector.

ALEMBIC PHARMACEUTICALS

BSE: 533573 30 Sep 2025

Healthcare

₹ 972.5

ALEMBIC PHARMACEUTICALS LIMITED specializes in Pharmaceuticals within the Healthcare sector.

Book Value

264.0

Dividend Yield

1.21%

Debt to Equity

0.24

Stock P/E

30.2

Market Cap

17,885 Cr

ALEMBIC PHARMACEUTICALS - Share Price & Details

Market Cap

₹17,885

High /Low

1,304 / 725.0

Stock P/E

30.2

Book Value

₹264.0

Dividend Yield

1.21

ROCE

13.0

ROE

₹11.4

Face Value

2.0

PEG Ratio

9.48

EVEBITDA

₹17.3

Debt

1,258

CMP / FCF

177.0

Debt to equity

₹0.24

NP Ann

582

High price all time

1,304

Piotroski score

₹5.0

Graham Number

427.0

No. Eq. Shares

19.7

Net CF

₹-36.7

Net profit

601

Price to book value

3.45

Interest Coverage

₹9.16

Low price all time

31.0

Industry PE

33.0

Reserves

₹5,152

Free Cash Flow

₹-466

Broker Recommendations

Date	Author	Type	Reco Price	Target Price	Potential	Source	PDF Link
06 Aug 2025	ICICI Securities	Hold	₹946.9	₹900	-5%	moneycontrol	View
05 Aug 2025	Motilal Oswal	Hold	₹946.9	₹990	5.7%	moneycontrol	View
06 May 2025	Motilal Oswal	Hold	₹887.6	₹930	3.6%	moneycontrol	View
06 Feb 2025	KRChoksey	Hold	₹894.2	₹909	1.5%	moneycontrol	View
04 Feb 2025	ICICI Securities	Hold	₹880.35	₹925	5.7%	moneycontrol	View
03 Feb 2025	Motilal Oswal	Hold	₹908.5	₹970	9.1%	moneycontrol	View
08 Nov 2024	KRChoksey	Hold	₹1,039	₹1,087	-1.1%	moneycontrol	View
07 Nov 2024	Motilal Oswal	Hold	₹1,081.45	₹1,110	0.9%	moneycontrol	View
14 May 2024	KRChoksey	Hold	₹963.95	₹986	-10.3%	moneycontrol	View
14 May 2024	Motilal Oswal	Hold	₹963.95	₹960	-12.6%	moneycontrol	View

Price Chart

Volume Chart

Peer Comparison

Stock	Total Income	Net Profit	Net Sales	EPS	Market Cap (in Cr)	P/E
FABINO ENTERPRISES LIMITED	NA	NA	NA	NA	5.09	84.8
Triochem Products Ltd.,	NA	NA	NA	NA	0
ALEMBIC PHARMACEUTICALS LTD.	15019.6	1035.2	14941.7	5.27	17,885	30.2
530019	602.0	58.0	595.0	0.26	16613	34.2
Concord Biotech Limited	2176.65	425.65	2039.88	4.07	16377	46.0

Peer Comparison Chart

About ALEMBIC PHARMACEUTICALS

ALEMBIC PHARMACEUTICALS LIMITED, with Security Code 533573, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.

Order Book

Latest News

Alembic Pharmaceuticals receives EIR for API - I and API - II facility located at Panelav

(16 Sep 2025)

Alembic Pharmaceuticals Limited has received the Establishment Inspection Report (EIR) for the inspection conducted by the US Food and Drug...

Alembic Pharmaceuticals Limited receives Establishment Inspection Report (EIR) for its API - I & API - II Facility located at Panelav.

(16 Sep 2025)

Mumbai: Alembic Pharmaceuticals Limited has received the Establishment Inspection Report (EIR) for the inspection conducted by the US Food...

Quarterly Table

Standalone Consolidated

Metrics	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Jun 2025
Sales	1,310.2	1,307.1	1,332.3	1,478.8	1,588.4	1,474.6	1,475.6	1,580.3	1,406.1	1,494.2
Expenses	1,086.0	1,137.9	1,166.5	1,271.4	1,251.2	1,186.4	1,184.1	1,320.9	1,226.3	1,280.4
Operating Profit	224.2	169.2	165.7	207.5	337.1	288.2	291.4	259.5	179.8	213.7
OPM %	17.11%	12.94%	12.44%	14.03%	21.23%	19.54%	19.75%	16.42%	12.79%	14.3%
Other Income	0.6	2.0	11.8	9.0	3.3	7.2	3.1	28.9	15.5	7.8
Interest	14.7	13.6	14.3	15.4	14.7	10.1	12.7	18.3	21.8	22.6
Depreciation	65.8	73.5	65.8	67.2	69.1	69.1	68.7	70.1	69.7	73.4
Profit before tax	144.3	84.0	97.5	133.8	256.7	216.2	213.2	187.1	103.8	125.5
Tax %	-17.4%	55.4%	0%	0%	-9.1%	-6.6%	17.4%	-17.1%	-17.3%	17.5%
Net Profit	119.1	130.6	97.5	133.8	233.2	201.9	176.2	165.8	85.8	103.5
EPS in Rs	6.06	6.64	4.96	6.81	11.87	10.27	8.96	8.43	4.37	5.27

Metrics	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	1,509.0	1,406.4	1,486.1	1,594.9	1,630.6	1,517.0	1,561.7	1,648.0	1,692.7	1,769.6
Expenses	1,273.9	1,202.7	1,287.5	1,387.2	1,364.3	1,257.3	1,324.9	1,408.7	1,432.5	1,498.4
Operating Profit	235.2	203.8	198.7	207.7	266.3	259.7	236.8	239.3	260.2	271.3
OPM %	15.58%	14.49%	13.37%	13.03%	16.33%	17.12%	15.16%	14.52%	15.37%	15.33%
Other Income	0.4	0.9	11.7	10.2	2.9	3.6	2.1	29.6	9.5	14.2
Interest	14.6	14.4	14.4	15.7	15.2	10.9	13.2	18.8	22.3	24.5
Depreciation	66.5	74.1	66.2	67.6	69.4	69.5	69.0	70.5	70.0	69.0
Profit before tax	154.5	116.2	129.8	134.6	184.6	182.8	156.7	166.7	177.4	192.0
Tax %	-19.4%	29.2%	-7.1%	1.4%	-2.2%	-2.5%	-14.4%	15.2%	22.6%	-18.3%
Net Profit	121.9	152.6	120.6	136.6	180.5	178.2	134.5	153.1	137.7	156.6
EPS in Rs	6.2	7.76	6.14	6.95	9.18	9.07	6.85	7.79	7.01	0

Shareholding Distribution

Shareholding Pattern

Compounded Data

Consolidated

Standalone

Compounded Sales Growth
10 Years:	12%
5 Years:	8%
3 Years:	6%
TTM:	3%

Compounded Profit Growth
10 Years:	6%
5 Years:	-13%
3 Years:	-3%
TTM:	-26%

Stock Price CAGR
10 Years:	6%
5 Years:	2%
3 Years:	9%
1 Year:	1%

Compounded Sales Growth
10 Years:	12%
5 Years:	8%
3 Years:	8%
TTM:	7%

Compounded Profit Growth
10 Years:	7%
5 Years:	-7%
3 Years:	3%
TTM:	-7%

Stock Price CAGR
10 Years:	6%
5 Years:	2%
3 Years:	9%
1 Year:	1%

All Deals

Date	Stock	Party	Deal	Acq. Mode	Trans.	Quan.	Price	Value

Stock Mutual Funds Data

Order Book

News Date ▲▼	Headline ▲▼	Issuer Entity ▲▼	Issuer Type ▲▼	Order Size ▲▼	Time Period ▲▼
Loading company updates…

Loading technicals…

Moving Averages

Latest Close: — • Records Used: — • Last Trading Date: —

Simple Moving Averages (SMA)

Period	SMA Value	Status

Exponential Moving Averages (EMA)

Period	EMA Value	Status

Oscillators

Key Oscillators

latest calculation

Indicator	Value

ALEMBIC PHARMACEUTICALS

ALEMBIC PHARMACEUTICALS

ALEMBIC PHARMACEUTICALS - Share Price & Details

Broker Recommendations

Price Chart

Volume Chart

Peer Comparison

Peer Comparison Chart

About ALEMBIC PHARMACEUTICALS

Order Book

Latest News

Alembic Pharmaceuticals receives EIR for API - I and API - II facility located at Panelav

Alembic Pharmaceuticals Limited receives Establishment Inspection Report (EIR) for its API - I & API - II Facility located at Panelav.

Alembic Pharma Gets EIR for API-I & II Facility at Panelav

Alembic Pharma Receives USFDA Compliance Report for Panelav Facilities

Briefs: Alembic Pharmaceuticals and Tyche Industries

USFDA clears Alembic Pharma’s Panelav manufacturing units after inspection

Alembic Pharma gets USFDA EIR for 2 API facilities in Panelav

Alembic Pharma wins USFDA approval for pulmonary arterial hypertension drug Macitentan

Alembic Pharmaceuticals Limited receives USFDA Final Approval for Macitentan Tablets

Alembic Pharma Gets USFDA Nod for Macitentan Tablets

Alembic Pharmaceuticals Limited receives USFDA Final Approval for Macitentan Tablets, 10mg

Alembic Pharma Gets USFDA Nod for Tretinoin Cream

Alembic Pharma Q1FY26 PAT Up 15% YoY to ₹154 Crore

Analysts Are Updating Their Alembic Pharmaceuticals Limited (NSE:APLLTD) Estimates After Its First-Quarter Results

Alembic Pharmaceuticals Q1 FY26 revenue up 10%; Net profit up 15%

Alembic Pharma Q1 Results: Net profit rises 15%, revenue up 10%

12 Dividend Stocks: SRF, Alembic Pharma, Punjab & Sind Bank — Last Day To Buy Shares To Qualify

Alembic Pharma gets USFDA nod for anticonvulsant drug Carbamazepine Extended Release

Bullish Pattern Emerging on Alembic Pharmaceuticals Limited (APLLTD) - Rapidly expanding wealth

Macro Trends and Their Impact on Alembic Pharmaceuticals Limited (APLLTD) - High-yield investments

Alembic Pharmaceuticals Limited (533573) Hits 52 Week High - High-yield capital appreciation

Bullish Pattern Emerging on Alembic Pharmaceuticals Limited (533573) - Phenomenal wealth increase

Alembic Pharmaceuticals Limited (APLLTD) Sees Unusual Trading Volume - Accelerated capital growth

Alembic Pharmaceuticals Limited (533573) Gets Regulatory Approval - Exceptional portfolio growth

Alembic Pharmaceuticals Limited (533573) Sees Unusual Trading Volume - High-octane gains

Alembic Pharmaceuticals Appoints Sachin Ghosalkar as Sr. VP - SCM & Operations

Alembic Pharmaceuticals Limited (APLLTD) vs yyy - Explosive trading growth

Alembic Pharmaceuticals Limited (APLLTD) vs yyy - Lightning-fast capital gains

Alembic Pharma ropes in Dr Sachin Ghosalkar as Sr Vice President - SCM & Operations

Alembic Pharmaceuticals Limited (533573) to Launch New Product Line - Unmatched market performance

Alembic Pharmaceuticals (NSEI:APLLTD) - Stock Price, News & Analysis

Alembic Pharma surges over 12% on USFDA approval for Cancer drug

Alembic Pharma's Karakhadi API facility in Gujarat gets an EIR from the USFDA

Why is Alembic Pharmaceuticals' share in demand today? Key details here

Alembic Pharma Share Price Falls After $12 Million US Acquisition Of Utility Therapeutics

Alembic Pharmaceuticals up 2% as arm acquires Utility Therapeutics; details

Alembic Pharma Viraj Save resigned as Executive Vice President - Sales and Marketing

Alembic Pharma Secures EIR from USFDA

Alembic Pharma gets USFDA EIR for API III facility at Karakhadi

Alembic Pharma Shares Slump 2% on 4 Observations

Alembic Pharma shares rise after getting USFDA approval for blood cancer drug

Alembic Pharma Shares Rose 2% on USFDA Nod

Alembic Pharmaceuticals announces USFDA final approval for Amlodipine and Atorvastatin Tablets USP

Alembic Pharma bags USFDA nod for high BP traetment drug

Alembic Pharmaceuticals Limited announces USFDA Final Approval for Amlodipine and Atorvastatin Tablets USP

Alembic Pharmaceuticals receives USFDA final approval for Rivaroxaban Tablets USP

Alembic Pharma appoints Jigr Shah as Head - Business Finance

Alembic Pharmaceuticals Limited announces USFDA Final Approval for Rivaroxaban Tablets USP, 2.5 mg, 10 mg, 15 mg, and 20 mg

Alembic Pharmaceuticals Receives USFDA Final Approval For Rivaroxaban Tablets

Briefs: Alembic Pharmaceuticals and Bafna Pharmaceuticals

Here's What Analysts Are Forecasting For Alembic Pharmaceuticals Limited (NSE:APLLTD) After Its Annual Results

Alembic Pharmaceuticals posts Q4 FY25 consolidated PAT at Rs. 156.63 Cr

Alembic Pharma Dividend 2025: 550% cash reward ANNOUNCED in Q4 results- Check quarterly earnings details

Alembic Pharma bags USFDA nod for cardiovascular disease drug Ticagrelor in two strengths

Alembic Pharma Gets USFDA Final Nod for Ticagrelor 90 mg and Tentative Approval for 60 mg

Alembic Pharmaceuticals Receives USFDA Approval For Ticagrelor Tablets

Alembic Pharma gains after receiving EIR from USFDA for Panelav facility

Alembic Pharma Shares Soar 3% as Panelav Unit Secures EIR

STOCKS IN NEWS: Kfin Technologies, Suzlon Energy, Alembic Pharmaceuticals, Glenmark Pharms, Puravankara, Idfc First Bank, Tata Steel, Indian Railway Finance Corporation, Power Grid Corp.Of India, Garden Reach Shipbldrs & Engs and others

Alembic Pharma gets final US FDA nod for Carbamazepine tablets

Alembic Pharmaceuticals Ltd

Briefs: Alembic Pharmaceuticals and Shelter Pharma

Volumes spurt at Alembic Pharmaceuticals Ltd counter

Alembic Pharmas Karakhadi API Facility Clears USFDA Inspection

Alembic Pharma's Vadodara unit passes FDA test with VAI remark

Alembic Pharma Q3 Results: Consolidated net profit declines 23% to ₹138 crore, stock down 5%

Q3FY25: Alembic Pharma’s profit dips 23.29 percent to Rs 138.42 crore

Alembic announces USFDA final approval for Brexpiprazole Tablets

Alembic Pharmaceuticals gets USFDA nod for generic antidepressant tablets